{"id":125,"date":"2014-04-18T15:07:59","date_gmt":"2014-04-18T15:07:59","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=125"},"modified":"2014-08-31T16:31:21","modified_gmt":"2014-08-31T20:31:21","slug":"waraboutdataaccess","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2014\/04\/18\/125\/waraboutdataaccess\/","title":{"rendered":"The War about Data Access"},"content":{"rendered":"

\"Tamiflu<\/a>Several articles in the April 7 issue of BMJ were devoted to the epic battle fought by BMJ and Cochrane to gain unfettered access to the Tamiflu\u00ae and Relenza\u00ae data. Not just some data, but all the data. Considering that only 2 out of 10 Tamiflu studies were published in 2010, this request for complete data sets made good sense. Was industry afraid that their results would not hold up to scrutiny by independent statistical re-analysis? Were there secrets locked up in company vaults?<\/p>\n

Eventually Roche and GSK provided complete data sets and permitted Cochrane statisticians to check the clinical trial data. Overall, this effort confirmed that the efficacy of the neuraminidase inhibitors is moderate and unimpressive: for Tamiflu, treatment shortens the time to first alleviation of symptoms by 16.8 hours (p<0.001); while prophylaxis reduces symptomatic influenza in household contacts and protects individuals post-exposure. Importantly, there was no reduction in hospital admissions and no effect on influenza complications (although the companies would dispute this). Regarding safety, most adverse events were trivial GI complaints but a very small minority of patients had significant neuropsychiatric AEs. Obviously, the Cochrane researchers felt that the benefits did not outweigh the risks, and certainly not the costs with stockpiling.<\/p>\n

For those of you who believed that neuraminidase inhibitors were potent influenza drugs, these conclusions may come as a surprise. However, most of us already knew that these drugs had at best a small benefit. The potential for CNS side effects was not a new finding, either. After all, FDA warned prescibers of neuropsychiatric problems in the label. So, overall, no big surprises, really.<\/p>\n

We could stop this blog here but to this \u2018war for data access\u2019 brought some rarely discussed practice patterns to the fore:<\/p>\n

\u2022 There is huge mistrust of industry practices related to data generation and interpretation. There is an implicit assumption that trial data are presented in a particularly industry-friendly fashion. However, the Cochrane efforts detected no bias or poor statistical work on part of the sponsors.
\n\u2022 The tendency in industry to prioritize the publication of \u2018favorable\u2019 data while delaying the release of other studies is a disgrace and has to stop. Content and timing of publications should not be decided by marketing strategists.
\n\u2022 EMA had less data for review than FDA which had full data sets. Seems that FDA did its own analysis of the raw data while EMA worked from company documents. This seems to be the underlying reason for differences in labeling details which prompted the Cochrane analysis in the first place.
\n\u2022 As with all anti-infectives, the benefit : risk ratio worsens over time as \u2018resistance creep\u2019 reduces the efficacy numerator. Rare but serious side events are hard to accept when benefits are small and keep getting smaller. Without lowering mortality from influenza, or reducing complications or hospitalizations, these drugs are clearly not life-savers when administered after the onset of symptoms.<\/p>\n","protected":false},"excerpt":{"rendered":"

Several articles in the April 7 issue of BMJ were devoted to the epic battle fought by BMJ and Cochrane to gain unfettered access to the Tamiflu\u00ae and Relenza\u00ae data. Not just some data, but all the data. Considering that only 2 out of 10 Tamiflu studies were published in Continue reading The War about Data Access<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[18],"tags":[14,11,12,13,8,15,16,9,10],"class_list":["post-125","post","type-post","status-publish","format-standard","hentry","category-the_viewpoint","tag-bmj","tag-cochrane","tag-data-access","tag-data-disclosure","tag-efficacy","tag-influenza","tag-neuraminidase-inhibitors","tag-safety","tag-tamiflu"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-21","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":2271,"url":"https:\/\/allphasepharma.com\/dir\/2016\/01\/31\/2271\/moving-towards-greater-transparency-one-step-at-a-time-inexorably\/","url_meta":{"origin":125,"position":0},"title":"Moving Towards Greater Transparency \u2013 One Step At A Time, Inexorably","author":"Harald","date":"January 31, 2016","format":false,"excerpt":"Sharing trial data has been a controversial topic for quite a while. Recently the editors of major medical journals decided to take a stand. They will\u00a0make access to trial source data a requirement, as a condition of publication, arguing that patients and the scientific community have a right to this\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Cleaning Up - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/01\/Cleaning-Up-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/01\/Cleaning-Up-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/01\/Cleaning-Up-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1629,"url":"https:\/\/allphasepharma.com\/dir\/2015\/06\/29\/1629\/nitrofurantoin-an-old-drug-resurrected-needs-prospective-scrutiny\/","url_meta":{"origin":125,"position":1},"title":"Nitrofurantoin \u2013 An Old Drug Resurrected Needs Prospective Scrutiny","author":"Harald","date":"June 29, 2015","format":false,"excerpt":"When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited\u00a0data, often considered incomplete by today\u2019s standards.\u00a0 Take colistin as an example: approved in the early 60ies, we still\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"UTI - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":354,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/21\/354\/the-rapid-rise-of-sulfonamide-diversity\/","url_meta":{"origin":125,"position":2},"title":"The Rapid Rise of Sulfonamide Diversity","author":"Harald","date":"June 21, 2014","format":false,"excerpt":"Shortly after Domagk and H\u00f6rlein announced their discovery of the antibacterial properties of the dye sulfamidochrysoidine (Prontosil) in 1935, numerous\u00a0chemical companies\u00a0set out to\u00a0modify the chemical structure. \u00a0They soon recognized the sulfa component as the true antibacterial and produced an incredible number of derivatives (more than 5000 different compounds!!) by 1945.[1,\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Prontosil","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/06\/Prontosil-300x136.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":5735,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/08\/5735\/comparison-of-baff-april-inhibitors-2\/","url_meta":{"origin":125,"position":3},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS \u2013 2","author":"Harald","date":"November 8, 2025","format":false,"excerpt":"Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept.\u00a0 This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] \u00a0We updated our table with this new information that centers on\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5771,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","url_meta":{"origin":125,"position":4},"title":"TACICEPTS VYING FOR YOUR ATTENTION","author":"Harald","date":"November 17, 2025","format":false,"excerpt":"Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the \"Late-Breaking Research\" session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":228,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/03\/228\/and-the-results-are-pending\/","url_meta":{"origin":125,"position":5},"title":"And the Results are \u2026Pending","author":"Harald","date":"June 3, 2014","format":false,"excerpt":"The website \u201cClinicalTrials.gov\u201d has become the first stop for many of us who need to check on trial activity of a particular drug.\u00a0 All larger human Phase 2 - 4 trials are listed there in quite some detail.\u00a0 While companies sometimes shy away from publishing full entry criteria or primary\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=125"}],"version-history":[{"count":8,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/125\/revisions"}],"predecessor-version":[{"id":831,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/125\/revisions\/831"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}